Skip to main content
Signal8
Launch Terminal

Immunovant, Inc. (IMVT)

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Immunovant, Inc. logo

Immunovant, Inc.

NASDAQ:IMVTHealthcare
-1.59%$29.17
AH$29.17+0.00%vs close
Mkt Cap$6.03B
Float86.67M
O/S206.55M
Vol
$ Vol
RVOL
Inst Own54.1%
SI21.1%
Earnings
Dilution
Immunovant, Inc. logoNASDAQ:IMVT$29.17-1.59%
Phase Distribution
19 lead-sponsored trials·8 active·5 completed
Phase 214
Phase 35
Status Overview
Recruiting5
Active, not recruiting3
Completed5
Stopped6

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Terminated

    Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

    Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly

    Generalized Myasthenia Gravis

    Enrollment
    233
    Start
    Jun 2022
    Primary Completion
    Jan 2025
    Completion
    Aug 2026
    NCT05403541
  • Phase 3
    Completed

    Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

    Batoclimab, Placebo

    Thyroid Eye Disease

    Enrollment
    114
    Start
    Nov 2022
    Primary Completion
    Nov 2025
    Completion
    Nov 2025
    NCT05517421
  • Phase 3
    Terminated

    Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

    Batoclimab

    Thyroid Eye Disease

    Enrollment
    109
    Start
    Nov 2022
    Primary Completion
    Apr 2026
    Completion
    Apr 2026
    NCT05517447
  • Phase 3
    Completed

    Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

    Batoclimab, Placebo

    Thyroid Eye Disease

    Enrollment
    86
    Start
    Jan 2023
    Primary Completion
    Feb 2026
    Completion
    Mar 2026
    NCT05524571
  • Phase 3
    Recruiting

    Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

    IMVT-1402, IMVT-1402

    Generalized Myasthenia Gravis

    Enrollment
    231
    Start
    May 2025
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2028est.
    NCT07039916
  • Phase 2
    Completed

    A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

    RVT-1401, Placebo

    Myasthenia Gravis

    Enrollment
    17
    Start
    May 2019
    Primary Completion
    Oct 2020
    Completion
    Dec 2020
    NCT03863080
  • Phase 2
    Completed

    Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)

    RVT-1401

    Graves' Ophthalmopathy

    Enrollment
    7
    Start
    Apr 2019
    Primary Completion
    Feb 2020
    Completion
    May 2020
    NCT03922321
  • Phase 2
    Terminated

    ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

    RVT-1401 (Administered via subcutaneous injection)

    Graves' Ophthalmopathy (GO)

    Enrollment
    65
    Start
    Jul 2019
    Primary Completion
    Feb 2021
    Completion
    Apr 2021
    NCT03938545
  • Phase 2
    Terminated

    To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).

    RVT-1401 680 mg/weekly, RVT-1401 340 mg/weekly

    Warm Autoimmune Hemolytic Anemia

    Enrollment
    5
    Start
    Aug 2020
    Primary Completion
    Apr 2021
    Completion
    Apr 2021
    NCT04253236
  • Phase 2
    Terminated

    To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

    Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly

    Chronic Inflammatory Demyelinating Polyneuropathy

    Enrollment
    94
    Start
    Dec 2022
    Primary Completion
    Jul 2026
    Completion
    Jul 2026
    NCT05581199
  • Phase 2
    Completed

    A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease

    IMVT-1401 (batoclimab)

    Graves Disease

    Enrollment
    32
    Start
    May 2023
    Primary Completion
    Jul 2025
    Completion
    Jul 2025
    NCT05907668
  • Phase 2
    Recruiting

    A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

    IMVT-1402, IMVT-1402

    Graves' Disease

    Enrollment
    240
    Start
    Dec 2024
    Primary Completion
    Jun 2028est.
    Completion
    Jun 2028est.
    NCT06727604
  • Phase 2
    Active, not recruiting

    A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

    IMVT-1402, Placebo

    Rheumatoid Arthritis

    Enrollment
    120
    Start
    Jan 2025
    Primary Completion
    Sep 2027est.
    Completion
    Sep 2027est.
    NCT06754462
  • Phase 2
    Active, not recruiting

    Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

    IMVT-1402, Placebo

    Primary Sjögren's Syndrome

    Enrollment
    180
    Start
    Jun 2025
    Primary Completion
    Jul 2028est.
    Completion
    Jul 2029est.
    NCT06979531
  • Phase 2
    Active, not recruiting

    A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

    IMVT-1402, Placebo

    Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

    Enrollment
    56
    Start
    Feb 2025
    Primary Completion
    Oct 2026est.
    Completion
    Apr 2027est.
    NCT06980805
  • Phase 2
    Recruiting

    A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

    IMVT-1402, IMVT-1402

    Graves' Disease

    Enrollment
    210
    Start
    Jun 2025
    Primary Completion
    May 2027est.
    Completion
    May 2027est.
    NCT07018323
  • Phase 2
    Recruiting

    Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    Imeroprubart, Placebo

    Chronic Inflammatory Demyelinating Polyneuropathy

    Enrollment
    162
    Start
    Mar 2025
    Primary Completion
    Aug 2028est.
    Completion
    May 2030est.
    NCT07032662
  • Phase 2
    Terminated

    An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    Batoclimab

    Chronic Inflammatory Demyelinating Polyneuropathy

    Enrollment
    26
    Start
    Aug 2025
    Primary Completion
    Jul 2026
    Completion
    Jul 2026
    NCT07188844
  • Phase 2
    Enrolling by invitation

    A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

    IMVT-1402

    Graves' Disease

    Enrollment
    372
    Start
    Jan 2026
    Primary Completion
    Mar 2030est.
    Completion
    Mar 2030est.
    NCT07286006
Search ClinicalTrials.gov for “Immunovant”